Literature DB >> 33994309

High occurrence of witnessing an opioid overdose in a sample of women who use heroin in Tanzania: Implications for overdose prevention.

Haneefa T Saleem1, Samuel Likindikoki2, Bareng A S Nonyane3, Jessie Mbwambo4, Carl Latkin5.   

Abstract

BACKGROUND: Opioid overdose is preventable and reversible. To target overdose prevention training and naloxone distribution, it is important to understand characteristics of those people who use drugs most likely to witness an overdose. In this paper we report the proportion and characteristics of women who use heroin that have witnessed an opioid overdose in Dar es Salaam, Tanzania.
METHODS: We conducted a cross-sectional survey with 200 women who use heroin. We fitted unadjusted and adjusted logistic regression models with witnessing an opioid overdose as the dependent variable and sociodemographic and drug use-related variables as independent variables.
RESULTS: The majority of participants (85%) reported having ever witnessed an opioid overdose. Age (adjusted Odds Ratio [aOR] = 1.09; 95% CI: 1.02-1.12), having ever attempted to stop heroin use (aOR = 11.27; 95% CI: 2.25-56.46), history of arrest (aOR = 3.75; 95% CI: 1.32-10.63), and spending time daily in places where people use drugs (aOR = 3.72; 95% CI: 1.43-9.64) were found to be independently associated with ever witnessing an overdose.
CONCLUSIONS: Findings suggest the need for expanded access to naloxone to lay people and community and peer-based overdose prevention training in Tanzania, including the distribution of naloxone in settings with high drug use.
Copyright © 2021 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Heroin; Overdose; Tanzania; Women

Mesh:

Substances:

Year:  2021        PMID: 33994309      PMCID: PMC8568619          DOI: 10.1016/j.drugpo.2021.103287

Source DB:  PubMed          Journal:  Int J Drug Policy        ISSN: 0955-3959


  8 in total

1.  Characteristics of drug users who witness many overdoses: implications for overdose prevention.

Authors:  Amy S B Bohnert; Melissa Tracy; Sandro Galea
Journal:  Drug Alcohol Depend       Date:  2011-08-12       Impact factor: 4.492

2.  Neighborhood-Level and Spatial Characteristics Associated with Lay Naloxone Reversal Events and Opioid Overdose Deaths.

Authors:  Christopher Rowe; Glenn-Milo Santos; Eric Vittinghoff; Eliza Wheeler; Peter Davidson; Philip O Coffin
Journal:  J Urban Health       Date:  2016-02       Impact factor: 3.671

3.  Generating trust: Programmatic strategies to reach women who inject drugs with harm reduction services in Dar es Salaam, Tanzania.

Authors:  Sophia Zamudio-Haas; Bathsheba Mahenge; Haneefa Saleem; Jessie Mbwambo; Barrot H Lambdin
Journal:  Int J Drug Policy       Date:  2016-01-23

Review 4.  Worldwide Prevalence and Trends in Unintentional Drug Overdose: A Systematic Review of the Literature.

Authors:  Silvia S Martins; Laura Sampson; Magdalena Cerdá; Sandro Galea
Journal:  Am J Public Health       Date:  2015-11       Impact factor: 9.308

5.  Correlates of Non-fatal, Opioid Overdose among Women Who Use Opioids in Dar es Salaam, Tanzania.

Authors:  Haneefa T Saleem; Samuel Likindikoki; Bareng A S Nonyane; Iddi Haruna Nkya; Leanne Zhang; Jessie Mbwambo; Carl Latkin
Journal:  Drug Alcohol Depend       Date:  2020-11-24       Impact factor: 4.492

6.  Effectiveness of bystander naloxone administration and overdose education programs: a meta-analysis.

Authors:  Rebecca E Giglio; Guohua Li; Charles J DiMaggio
Journal:  Inj Epidemiol       Date:  2015-05-22

7.  Barriers to and recommendations for take-home naloxone distribution: perspectives from opioid treatment programs in New Mexico.

Authors:  Julie G Salvador; Andrew L Sussman; Mikiko Y Takeda; William G Katzman; Monica Moya Balasch; Joanna G Katzman
Journal:  Harm Reduct J       Date:  2020-05-13

Review 8.  Are take-home naloxone programmes effective? Systematic review utilizing application of the Bradford Hill criteria.

Authors:  Rebecca McDonald; John Strang
Journal:  Addiction       Date:  2016-03-30       Impact factor: 6.526

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.